ANI Pharmaceuticals' GAAP loss for 3 months of 2022 was $20.13 million, compared to a profit of $0.086 million in the previous year. Revenue increased 18.3% to $64.477 million from $54.521 million a year earlier.
Warning BlackTerminal uses cookies in order to personalize and improve the usability of the service. If you do not want to use cookies, please change your browser settings. Accept